Fulvestrant Injection 250 mg/5 mL (50 mg/mL) For Intramuscular Use Only Contains 2 single-dose pr...

FDA Drug Recall #D-0820-2021 — Class II — August 27, 2021

Recall Summary

Recall Number D-0820-2021
Classification Class II — Moderate risk
Date Initiated August 27, 2021
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Glenmark Pharmaceuticals Inc., USA
Location Mahwah, NJ
Product Type Drugs
Quantity 28658 cartons

Product Description

Fulvestrant Injection 250 mg/5 mL (50 mg/mL) For Intramuscular Use Only Contains 2 single-dose pre-filled syringes Rx only NDC 68462-317-32

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

Nationwide.

Lot / Code Information

Lots: 30200014 Exp. 04/30/2022; 30200015 Exp. 05/31/2022; 30200015 Exp. 05/31/2022; 30200016 Exp. 05/31/2022; 30200036 Exp. 09/30/2022; 30200038 Exp. 09/30/2022; 30200039 Exp. 09/30/2022; 30200040 Exp. 09/30/2022; 30210001 Exp. 12/31/2022; 30210002 Exp. 12/31/2022; 30210003 Exp. 01/31/2023; 30210004 Exp. 01/31/2023; 30210005 Exp. 01/31/2023; 30210006 Exp. 01/31/2023; 30210014 Exp. 02/28/2023; 30210022 Exp. 02/28/2023; 30210028 Exp. 02/28/2023; 30210029 Exp. 02/28/2023; 30210030 Exp. 02/28/2023; 30210031 Exp. 02/28/2023

Other Recalls from Glenmark Pharmaceuticals Inc., USA

Recall # Classification Product Date
D-0246-2026 Class II Ondansetron Orally Disintegrating Tablets, USP,... Dec 30, 2025
D-0199-2026 Class III Bisoprolol Fumarate and Hydrochlorothiazide Tab... Nov 21, 2025
D-0222-2026 Class III Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, ... Nov 18, 2025
D-0662-2025 Class II Azelaic Acid Gel, 15%, 50 grams, For Topical Us... Sep 17, 2025
D-0021-2026 Class II Viorele, Desogestrel and Ethinyl Estradiol, USP... Sep 3, 2025

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.